 Home > Active Ingredient News > Antitumor Therapy > New progress has been made in the treatment of advanced ovarian cancer, and GEN-1 has achieved gratifying results in Phase I/II clinical trials!

New progress has been made in the treatment of advanced ovarian cancer, and GEN-1 has achieved gratifying results in Phase I/II clinical trials!

 Last Update: 2021-03-19
 Source: Internet
 Author: User

Tags

new treatment tourette's

liver disease progression

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Ovarian cancer mainly occurs in women aged 50-70.

Ovarian cancer

Biopharmaceutical company Celsion today announced the latest information on the I/II OVATION 2 study of GEN-1 for the treatment of advanced ovarian cancer.

immunity

The OVATION 2 study explored the effectiveness and safety of GEN-1 combined with standard new adjuvant chemotherapy (NACT) in the treatment of newly treated stage III/IV ovarian cancer.

The results of the OVATION 2 study showed that compared with the control group (standard of care only), the treatment group (standard of care + GEN-1) increased the patient’s progression-free survival by 33%.

Original source:

https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

N-Desmethyl Imatinib 99%

CAS No.: 404844-02-6

Pharma Grade

$1/MT FOB

High purity Octenidine dihydrochloride 98% with best price 70775-75-6 and Octenidine dihydrochloride raw material

CAS No.: 70775-75-6

Pharmacy Grade

$8.8-10/MT FOB

Anti-Cancer Pirespa Powder CAS 53179-13-8 Pirfenidone 5-methyl-1-phenylpyridin-2-one

CAS No.: 53179-13-8

Pharmacy Grade

$4/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.